The WHO Just Backed GLP-1s for Obesity. What Took So Long?

For years, the World Health Organization stood still.

While patients were gasping for air under the weight of obesity.

While scientists flooded journals with evidence.

While countries faced rising death rates tied to chronic weight-related conditions.

The WHO said nothing.

They didn’t list GLP-1s. They didn’t call obesity what it is. They didn’t act. And in that silence, millions suffered without access to the only class of medication proven to meaningfully treat this disease.

But this week, the silence broke.

The WHO has officially added GLP-1 medications to the Model List of Essential Medicines for the treatment of obesity. You can read it here, but I’ll be honest, it reads more like an overdue press release than a breakthrough declaration.

And yet, it matters. It matters a lot.

The Model List is not just symbolic. It influences global health systems. It tells governments and ministries of health which medicines should be considered nonnegotiable. It sets a standard. And for the WHO to finally recognize GLP-1s as essential for obesity means the excuses can start drying up.

But let’s not pretend this was an act of bold leadership. The WHO didn’t move until the evidence became undeniable. Until the pressure built too loud to ignore. Until it became clear that obesity was not just an issue of wealthier nations, but a growing crisis in every corner of the globe.

Why now? Maybe it’s the flood of real-world data. Maybe it’s the rising calls from advocacy groups, patients, and frontline clinicians. Maybe it’s the mounting global cost of untreated obesity. Or maybe it’s just that it became riskier to keep saying no than to finally say yes.

Either way, the delay cost people. It cost lives. And the gap between what we knew and what they were willing to admit is a reminder that institutions often move only when forced.

Still, this is a turning point. And it’s one that matters.

It tells insurers and policy makers that this is no longer experimental or fringe. It tells doctors that they are right to treat obesity with medication. And it tells patients what they have needed to hear all along: this is not your fault, and yes, there is treatment.

The WHO’s decision does not fix the cost problem. It does not suddenly make GLP-1s affordable in every country. But it clears a path. It removes one of the biggest bureaucratic barriers. And it gives patient advocates around the world a powerful new tool in the fight for access.

For those of us who have been shouting this truth for years, the WHO’s decision is not a revelation. It is a confirmation. A late one. But still a step forward.

If you’re reading this and you’ve been part of this movement, whether sharing, commenting, writing to lawmakers, standing up in clinics and online forums, this moment belongs to you too.

We made noise. And now, finally, the world is listening.

On The Pen is the first patient-driven platform focused entirely on news, access, and advocacy in obesity medicine. If this work matters to you, I hope you’ll subscribe. Paid members help me keep going.

Let’s keep pushing.